While West Virginia's employee health insurance program covers drugs like Ozempic for people with type 2 diabetes, officials ...
Breaking the silence on how generational trauma impacts obesity in Black communities, through one woman's powerful journey ...
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...
The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...
San Diego-based iBio has signed a backloaded agreement with its existing partner AstralBio for a preclinical anti-myostatin ...
Although bipartisan legislation to provide Medicare coverage for obesity treatments has circulated in Congress for more than ...
The statistics continue to be alarming, with no indication that the global rise in obesity is slowing. The real question ...
Since Zepbound was approved by the FDA to treat obesity in late 2023, its maker Eli Lilly has been steadily closing in on ...
I applaud the Biden administration’s recent moves to make these anti-obesity drugs more accessible to people on Medicaid and ...
On Thursday, iBio, Inc. (NYSE:IBIO) expanded its cardiometabolic and obesity treatment development program by in-licensing a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback